HealthTheStreetabout 5 hours ago
Goldman Sachs reaffirms Novo Nordisk stock target
4 min read
Goldman Sachs reaffirmed its Neutral rating and $47 price target on Novo Nordisk stock after meeting with management at a major healthcare conference. The decision signals the bank's view on where the GLP-1 race stands today. Novo has spent 2026 trying to convince investors the worst is behind it.
Level
Hype check
Tap to vote and see what everyone thinks.
